American Society of Hematology

Annual Meeting Registration

Advance registration for the 56th ASH® Annual Meeting is now open.

Learn more

State-of-the-Art Symposium

Featuring clinical hematology updates with a focus on lymphoid malignancies

Learn more

New NHLBI Report on Sickle Cell Disease

ASH endorses a new evidence-based expert panel report on the management of sickle cell disease published by the National Heart, Lung, and Blood Institute (NHLBI)

Learn more

Protect Medical Research

Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
View all press releases
  • ASH Comments on Proposals Covering Medicare Payments to Physicians and Hospitals in 2015

    ASH submitted comment letters covering Medicare proposals for payments and associated policies for services paid under the physician fee schedule and the hospital outpatient prospective payment system.

  • ASH and ASCO Co-Host Annual CAC Meeting

    On Friday July 25, 2014, ASH and the American Society of Clinical Oncology (ASCO) co-hosted the annual Hematology and Oncology Carrier Advisory Committee (CAC) network meeting. The meeting is intended to provide attendees with a better understanding of the CAC process; discuss issues of common concern and develop solutions; and improve the overall CAC process throughout the year.

  • CMS Announces Decision to Amend Policy that Had Required Prior Authorization for All Part D Drugs

    In June, ASH joined an effort to advocate that Medicare change recent rules that required Medicare patients who had entered hospice status to go through prior authorization for all prescription drugs.  ASH and the other organizations that worked on this issue felt that this requirement was a significant hurdle to be faced by patients whose disease had necessitated hospice status.

View all policy news
View all Hematologist articles